{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T20:44:46Z","timestamp":1773434686248,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T00:00:00Z","timestamp":1511308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015002","name":"Relypsa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.amjmed.2017.11.011","type":"journal-article","created":{"date-parts":[[2017,11,26]],"date-time":"2017-11-26T15:00:29Z","timestamp":1511708429000},"page":"555-564.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors"],"prefix":"10.1016","volume":"131","author":[{"given":"Matthew R.","family":"Weir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Bushinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1511-7490","authenticated-orcid":false,"given":"Wade W.","family":"Benton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven D.","family":"Woods","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha R.","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan P.","family":"Arthur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1183-1267","authenticated-orcid":false,"given":"George L.","family":"Bakris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2017.11.011_bib0010","first-page":"101","article-title":"Trends in aging\u2014United States and worldwide","volume":"52","author":"Centers for Disease Control and Prevention","year":"2003","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0015","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1053\/j.ackd.2010.03.010","article-title":"Chronic kidney disease and end-stage renal disease in the elderly population: current prevalence, future projections, and clinical significance","volume":"17","author":"Stevens","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0020","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1001\/archinternmed.2007.80","article-title":"Incidence and prevalence of heart failure in elderly persons, 1994-2003","volume":"168","author":"Curtis","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0025","first-page":"54","article-title":"General and psychotherapeutic medication use in 328 nursing facilities: a year 2000 national survey","volume":"16","author":"Tobias","year":"2001","journal-title":"Consult Pharm"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0030","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1034\/j.1600-0560.2002.56.x","article-title":"The 2030 problem: caring for aging baby boomers","volume":"37","author":"Knickman","year":"2002","journal-title":"Health Serv Res"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0035","doi-asserted-by":"crossref","first-page":"335","DOI":"10.5034\/inquiryjrnl_42.4.335","article-title":"Long-term care over an uncertain future: what can current retirees expect?","volume":"42","author":"Kemper","year":"2005","journal-title":"Inquiry"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0040","series-title":"Healthcare Cost and Utilization Project (HCUP) Statistical Briefs","article-title":"Conditions with the largest number of adult hospital readmissions by payer, 2011: statistical brief #172","author":"Hines","year":"2006"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0045","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1001\/archinte.168.22.2481","article-title":"Early and long-term outcomes of heart failure in elderly persons, 2001-2005","volume":"168","author":"Curtis","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0050","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0055","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0060","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","article-title":"Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data","volume":"135","author":"Jafar","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0065","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial","volume":"285","author":"Agodoa","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0070","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0075","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0080","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators","volume":"327","author":"Yusuf","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0085","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","article-title":"Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials","volume":"273","author":"Garg","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0090","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0095","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0100","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","author":"National Kidney Foundation","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0105","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1053\/j.ajkd.2014.01.416","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD","volume":"63","author":"Inker","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0110","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/CIR.0b013e31829e8807","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0115","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jacc.2016.05.011","volume":"68","author":"Yancy","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0120","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0125","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.2337\/dc17-S013","article-title":"10. Microvascular complications and foot care","volume":"40","author":"American Diabetes Association","year":"2017","journal-title":"Diabetes Care"},{"issue":"suppl 11","key":"10.1016\/j.amjmed.2017.11.011_bib0130","first-page":"S313","article-title":"Evaluation of clinical outcomes and costs based on prescribed dose level of renin-angiotensin-aldosterone system inhibitors","volume":"22","author":"Epstein","year":"2016","journal-title":"Am J Manag Care"},{"issue":"24","key":"10.1016\/j.amjmed.2017.11.011_bib0135","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","article-title":"Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study","volume":"38","author":"Ouwerkerk","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0140","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMra035279","article-title":"Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system","volume":"351","author":"Palmer","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0145","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1046\/j.1525-1497.1997.07128.x","article-title":"Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis","volume":"12","author":"Perazella","year":"1997","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0150","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2215\/CJN.07821109","article-title":"Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors","volume":"5","author":"Weir","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0155","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archinte.158.1.26","article-title":"Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?","volume":"158","author":"Reardon","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0160","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","article-title":"The frequency of hyperkalemia and its significance in chronic kidney disease","volume":"169","author":"Einhorn","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0165","doi-asserted-by":"crossref","first-page":"84","DOI":"10.5507\/bp.2012.087","article-title":"Arrhythmias and ECG changes in life threatening hyperkalemia in older patients treated by potassium sparing drugs","volume":"158","author":"Berkova","year":"2014","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0170","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/ndt\/gfp104","article-title":"Sudden death and associated factors in a historical cohort of chronic haemodialysis patients","volume":"24","author":"Genovesi","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0175","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00125-010-1922-6","article-title":"Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial","volume":"54","author":"Miao","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0180","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1080\/14656566.2016.1190333","article-title":"Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer","volume":"17","author":"Epstein","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0185","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0190","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/HYPERTENSIONAHA.115.04889","article-title":"New potassium binders for the treatment of hyperkalemia: current data and opportunities for the future","volume":"66","author":"Pitt","year":"2015","journal-title":"Hypertension"},{"issue":"2 suppl","key":"10.1016\/j.amjmed.2017.11.011_bib0195","first-page":"S27","article-title":"Managing hyperkalemia in high-risk patients in long-term care","volume":"23","author":"Kumar","year":"2017","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0200","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1177\/1074248416629549","article-title":"Mechanism of action and pharmacology of patiromer, a nonabsorbed cross-linked polymer that lowers serum potassium concentration in patients with hyperkalemia","volume":"21","author":"Li","year":"2016","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0205","series-title":"Veltassa (patiromer) for oral suspension [package insert]","author":"Relypsa, Inc.","year":"2016"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0210","author":"European Medicines Agency"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0215","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/ejhf.402","article-title":"Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors","volume":"17","author":"Pitt","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0220","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0225","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","article-title":"Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"issue":"suppl 1","key":"10.1016\/j.amjmed.2017.11.011_bib0230","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1097\/HJH.0000000000001278","article-title":"Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics","volume":"35","author":"Weir","year":"2017","journal-title":"J Hypertens"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0235","first-page":"S43","article-title":"Clinical and economic impact of hyperkalemia in patients with chronic kidney disease and heart failure (abstract)","volume":"22","author":"Polson","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0240","doi-asserted-by":"crossref","first-page":"237","DOI":"10.4172\/2329-9517.1000237","article-title":"Letter to the editor","volume":"4","author":"Bakris","year":"2016","journal-title":"J Cardiovasc Dis Diagn"},{"key":"10.1016\/j.amjmed.2017.11.011_bib0245","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.2215\/CJN.01170216","article-title":"Effect of patiromer on urinary ion excretion in healthy adults","volume":"11","author":"Bushinsky","year":"2016","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934317312032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934317312032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:28:38Z","timestamp":1762079318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934317312032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0002934317312032"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2017.11.011","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732188754.793541000","asserted-by":"object"}]},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2017.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2017.12.013","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}